The core business has returned to strong operating profitability and is positioned for significant earnings growth in the years ahead
Cost reduction initiatives for the assembly and manufacture of key products are yet to fully flow through to the bottom line, expected to occur in FY16
Push into the Chinese neurology market a massive, untapped and rapidly growing
opportunity. We are already no.1 in premium sleep diagnostics with extensive long term
relationships with major distributors.
New generation Grael to be released for sale Dec 2015
The company is currently considering options to simplify its
business and unlock significant value for shareholders by:
Spinning out its Germany based DWL Transcranial Doppler
(TCD) ultrasound blood flow business
Spinning out its Brain Research business (NeuroScan)
eHealthMedics has already locked in excess of $10m of forward orders over the next three years (primarily in China) for its professional services platform. Initial pilot sites commence in May and June this year
Compumedics are now approaching a select group of strategic partners/investors to expedite the process and rapidly deploy the platform to market
Key partners being pursued include web, telco, eHealth, consumer health/electronics providers and device manufacturers
-------------------------------------------
gltah
CMP Price at posting:
35.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)